Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy
- PMID: 31715127
- DOI: 10.1016/j.ccell.2019.10.012
Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy
Abstract
In this issue of Cancer Cell, Quereda and colleagues report that a newly developed specific inhibitor of CDK12/13, SR-4835, sensitizes triple-negative breast cancer cells to PARP inhibitors and DNA-damaging chemotherapeutics by reducing expression of the genes in the DNA damage response pathway.
Copyright © 2019 Elsevier Inc. All rights reserved.
Comment on
-
Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.Cancer Cell. 2019 Nov 11;36(5):545-558.e7. doi: 10.1016/j.ccell.2019.09.004. Epub 2019 Oct 24. Cancer Cell. 2019. PMID: 31668947
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials